keyboard_arrow_up

Erectile Dysfunction (ED) Drugs Market to Decline at 4.50% CAGR till 2019 due to Patent Expiration of Blockbuster Drugs

Transparency Market Research has recently published a detailed research report on the global erectile dysfunction drugs market. The research report, titled “Erectile Dysfunction Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019,” has studied the market using Porter’s five forces analysis to understand the threat of new entrants, the threat of substitute products or services, the bargaining power of suppliers, the intensity of competitive rivalry, and the bargaining power of customers. Furthermore, it also states the strengths, weaknesses, opportunities, and threats impacting the segments of the overall erectile dysfunction drugs market. 

Get Free Report Sample and Customization: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html

According to the research report published by Transparency Market Research, the global erectile dysfunction drugs market is likely to plummet in the near future to US$3.4 bn in 2019, from US$4.3 bn in 2012, declining at a negative CAGR of -4.5% from 2013 to 2019. The market is expected to experience a drop in the revenue, as several medicines are poised to reach patent expiration and the marketing exclusivity with it. This is likely to trigger a new hope of establishing a steady revenue flow for generic drug manufacturers as they will have an opportunity to launch their own medicines and brands. Furthermore, the poor success rate of new drugs due to weak pipeline development is also expected to create a drop in the earnings of the global erectile dysfunction drugs market

The global erectile dysfunction drugs market has been segmented on the basis of brand, drugs in the pipeline, and geography. The brands being sold in this market are Viagra (Sildenafil Citrate), Cialis (Tadalafil), Helleva (Lodenafil Carbonate), Levitra/Staxyn (Vardenafil), Zydena (Udenafil), Stendra/Spedra (Avanafil), MUSE (Medicated Urethral System for Erection), and Mvix (Mirodenafil). Some of the major drugs in the pipeline are Vitaros (Alprostadil), Uprima (Apomorphine), and others such as Melanocortin Activators, Topiglan, and Gene Therapy. Geographically, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

Despite the negative market sentiment, North America is expected to dominate the global erectile dysfunction drugs market due to the strong presence of topnotch drugs such as Viagra and Cialis in the U.S. all through 2019. According to the report, the North America erectile dysfunction drugs market stood at US$2.1 bn in 2012. The dominance does face certain challenges such as the loss of marketing exclusivity for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) in the coming three years. Furthermore, this market will also be hampered due to the influx of generic drugs, cost containment measures, and introduction of various cheaper products.

Some of the key players in the global erectile dysfunction drugs market are S.K. Chemicals, Bayer AG, Apricus Biosciences, Meda Pharmaceuticals, Dong-A Pharmaceutical, Pfizer, Eli Lilly And Company, and Vivus. The research report profiles these players and offers a comprehensive analysis of the competitive landscape of the global erectile dysfunction drugs market. The report also explains the regulatory framework governing the overall market. Furthermore, the management styles, research and development activities, investment outlook, product portfolio, joint ventures, business and marketing strategies, and strategic mergers and acquisitions of key players have been discussed in this report.

Browse Research Report on Erectile Dysfunction Drugs Market: http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html